Systemic Blockade of ACVR2B Ligands Attenuates Muscle Wasting in Ischemic Heart Failure Without Compromising Cardiac Function
Szabó, Z., Vainio, L., Lin, R., Swan, J., Hulmi, J. J., Rahtu-Korpela, L., Serpi, R., Laitinen, M., Pasternack, A., Ritvos, O., Kerkelä, R., & Magga, J. (2020). Systemic Blockade of ACVR2B Ligands Attenuates Muscle Wasting in Ischemic Heart Failure Without Compromising Cardiac Function. FASEB Journal, 34(8), 9911-9924. https://doi.org/10.1096/fj.201903074RR
Published inFASEB Journal
© 2020 The Authors
Signaling through activin receptors regulates skeletal muscle mass and activin receptor 2B (ACVR2B) ligands are also suggested to participate in myocardial infarction (MI) pathology in the heart. In this study, we determined the effect of systemic blockade of ACVR2B ligands on cardiac function in experimental MI, and defined its efficacy to revert muscle wasting in ischemic heart failure (HF). Mice were treated with soluble ACVR2B decoy receptor (ACVR2B-Fc) to study its effect on post-MI cardiac remodeling and on later HF. Cardiac function was determined with echocardiography, and myocardium analyzed with histological and biochemical methods for hypertrophy and fibrosis. Pharmacological blockade of ACVR2B ligands did not rescue the heart from ischemic injury or alleviate post-MI remodeling and ischemic HF. Collectively, ACVR2B-Fc did not affect cardiomyocyte hypertrophy, fibrosis, angiogenesis, nor factors associated with cardiac regeneration except modification of certain genes involved in metabolism or cell growth/survival. ACVR2B-Fc, however, was able to reduce skeletal muscle wasting in chronic ischemic HF, accompanied by reduced LC3II as a marker of autophagy and increased mTOR signaling and Cited4 expression as markers of physiological hypertrophy in quadriceps muscle. Our results ascertain pharmacological blockade of ACVR2B ligands as a possible therapy for skeletal muscle wasting in ischemic HF. Pharmacological blockade of ACVR2B ligands preserved myofiber size in ischemic HF, but did not compromise cardiac function nor exacerbate cardiac remodeling after ischemic injury. ...
PublisherJohn Wiley & Sons; Federation of American Societies for Experimental Biology
ISSN Search the Publication Forum0892-6638
Publication in research information system
MetadataShow full item record
- Liikuntatieteiden tiedekunta 
Related funder(s)Academy of Finland
Funding program(s)Academy Research Fellow, AoF
Additional information about fundingAcademy of Finland (Suomen Akatemia). Grant Numbers: 268505, 297094, 275922 Sydäntutkimussäätiö (Finnish Foundation for Cardiovascular Research)
Showing items with similar title or keywords.
Systemic blockade of ACVR2B ligands protects myocardium from acute ischemia-reperfusion injury Magga, Johanna; Vainio, Laura; Kilpiö, Teemu; Hulmi, Juha; Taponen, Saija; Lin, Ruizhu; Räsänen, Markus; Szabó, Zoltán; Gao, Erhe; Rahtu-Korpela, Lea; Alakoski, Tarja; Ulvila, Johanna; Laitinen, Mika; Pasternack, Arja; Koch, Walter J.; Alitalo, Kari; Kivelä, Riikka; Ritvos, Olli; Kerkelä, Risto (Cell Press, 2019)Activin A and myostatin, members of the transforming growth factor (TGF)-β superfamily of secreted factors, are potent negative regulators of muscle growth, but their contribution to myocardial ischemia-reperfusion (IR) ...
Automated detection and localization system of myocardial infarction in single-beat ECG using Dual-Q TQWT and wavelet packet tensor decomposition Liu, Jia; Zhang, Chi; Zhu, Yongjie; Ristaniemi, Tapani; Parviainen, Tiina; Cong, Fengyu (Elsevier B.V., 2020)Background and objective. It is challenging to conduct real-time identification of myocardial infarction (MI) due to artifact corruption and high dimensionality of multi-lead electrocardiogram ...
Systemic blockade of ACVR2B ligands prevents chemotherapy-induced muscle wasting by restoring muscle protein synthesis without affecting oxidative capacity or atrogenes Nissinen, Tuuli; Degerman, J.; Räsänen, M.; Poikonen, A. R.; Koskinen, S.; Mervaala, E.; Pasternack, A.; Ritvos, O.; Kivelä, R.; Hulmi, Juha (Nature Publishing Group, 2016)Doxorubicin is a widely used and effective chemotherapy drug. However, cardiac and skeletal muscle toxicity of doxorubicin limits its use. Inhibiting myostatin/activin signalling can prevent muscle atrophy, but its effects ...
Ideal cardiovascular health and risk of acute myocardial infarction among Finnish men Isiozor, Nzechukwu M.; Kunutsor, Setor K.; Voutilainen, Ari; Kurl, Sudhir; Kauhanen, Jussi; Laukkanen, Jari A. (Elsevier Ireland Ltd., 2019)Background and aims: Acute myocardial infarction (AMI) is associated with high mortality globally and remains a public health burden. We sought to investigate the relation between the American Heart Association’s cardiovascular ...
Targeting the Activin Receptor Signaling to Counteract the Multi-Systemic Complications of Cancer and Its Treatments Hulmi, Juha J.; Nissinen, Tuuli A.; Penna, Fabio; Bonetto, Andrea (MDPI, 2021)Muscle wasting, i.e., cachexia, frequently occurs in cancer and associates with poor prognosis and increased morbidity and mortality. Anticancer treatments have also been shown to contribute to sustainment or exacerbation ...